3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
3
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
8
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
3
Thyroid Neoplasms
2
Nasopharyngeal Carcinoma
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Cancer Extensive Stage
1
Proteinuria
1
Platinum-resistant Ovarian Cancer (PROC)
1
Pheochromocytoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Melanoma
1
Limited Stage Small Cell Lung Cancer
1
Fallopian Tube Neoplasms
1
Extensive Stage Lung Small Cell Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
Drug Therapy
3
Carboplatin
3
Surgical Procedures, Operative
2
Pemetrexed
2
Paclitaxel
2
Cisplatin
2
toripalimab
1
tislelizumab
1
surufatinib
1
osimertinib
1
lorlatinib
1
anlotinib
1
aflutinib
1
Radiotherapy
1
Radiosurgery
1
Platinum Compounds
1
Neoadjuvant Therapy
1
Diphenhydramine
1
Cryotherapy
1
Chemotherapy, Adjuvant
1
Chemoradiotherapy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
NSCLC
×
anlotinib
×
Clear all
NCT06182761
2023-12-27
WUKONG-9
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
45 enrolled